NVCR Stock Up

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success
Shares hit 52-week high as innovative treatment shows unprecedented survival rates, reshaping cancer care landscape
Novocure therapy succeeds in pancreatic cancer trial
Novocure (NVCR) achieves milestone in pancreatic cancer treatment with positive trial results for TTFields therapy, leading to a 25% surge in stock price.
Novocure's pancreatic cancer treatment meets main goal in late-stage study
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage trial.
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable,
Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.
NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer
NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer.
Stocktwits on MSN2d
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...
Fintel on MSN2d
Evercore ISI Group Upgrades NovoCure (NVCR)
Fintel reports that on December 2, 2024, Evercore ISI Group upgraded their outlook for NovoCure (NasdaqGS:NVCR) from In-Line ...
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on NVCR stock, giving a Buy rating today.Don't Miss our Black Friday ...
Navigating 5 Analyst Ratings For NovoCure
5 analysts have shared their evaluations of NovoCure NVCR during the recent three months, expressing a mix of bullish and ...
Investors Purchase Large Volume of Call Options on NovoCure (NASDAQ:NVCR)
NovoCure Limited (NASDAQ:NVCR – Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 4,528 call options on the stock. This represents an increase of 252% ...
NovoCure’s PANOVA-3 Trial Success Boosts Oncology Prospects
Wells Fargo analyst Larry Biegelsen has assigned their bullish stance on NVCR stock, giving a Buy rating yesterday.Don't Miss our Black Friday ...